PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dexamethasone - Diabetic macular oedema

PAD Profile : Dexamethasone - Diabetic macular oedema Important

Keywords :
DMO, Ophthalmology,
Brand Names Include :
Ozurdex
Important Information :
Ophthalmology specialists only

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal implant
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve intravitreal dexamethasone as a treatment option for the treatment of Diabetic Macular Oedema in line with NICE TA824. A Diabetic Macular Oedema (DMO) treatment pathway was also agreed by the APC and is attached  for information.

Intravitreal dexamethasone will be considered RED on the traffic light system.

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

25 May 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN decision of October 2015 was reviewed in May 2018 in regards to frequency of injections and the PCN agreed to the Ophthalmology Network proposal to allow some patients to have injections more frequently than every 6 months (no more frequently than 4 monthly). Please see below for further information

Associated BNF Codes

11. Eye
11.04.01. Corticosteroids
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More